Sign in
Taking people in South KoreaPhase 4

Tests enavogliflozin for heart failure after aortic valve replacement

Tests enavogliflozin, added to usual care, in adults with aortic valve narrowing and heart failure.

Key facts

Who runs it
Duk-Woo Park, MD
Where
Bucheon-si, Changwon, Daegu, Daejeon, Gangneung, Gwangju, Ilsan, Incheon, Pusan, Seongnam-si, Seoul, Suwon, Uijeongbu-si, and Ulsan, South KoreaSee the 31 sites
Trial code
Registry title
ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement
Status
Recruiting
Phase
Phase 4
People taking part
1,040 people, planned
Started
18 Dec 2024
Expected to end
Apr 2029
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Enavogliflozin
  • Standard-of-Care
Record updated
29 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who had a successful TAVR (a catheter-placed heart valve) for severe aortic stenosis and who have heart failure with a mildly reduced or preserved ejection fraction. It compares enavogliflozin with placebo.

Age
19 years or older
Sex
All sexes can join
Disease stage
Symptomatic aortic stenosis treated with a successful TAVR. Heart failure with left ventricular ejection fraction (LVEF) ≥40%, with a thickened left ventricle or an enlarged left atrium.
Earlier treatment
Must have had a successful transcatheter aortic valve replacement (TAVR). Cannot have taken an SGLT2 inhibitor within 4 weeks before randomization.
Biomarker or test result
NT-proBNP ≥ 300 pg/mL, or ≥ 600 pg/mL if atrial fibrillation is ongoing.

Main reasons for not taking part

  • Acute worsening of heart failure needing intravenous treatment after TAVR
  • Heart failure with reduced ejection fraction (LVEF <40%)
  • Type 1 diabetes or diabetic ketoacidosis
  • Severe kidney disease (eGFR <30 ml/min/1.73 m2) or dialysis
  • Pregnancy or breastfeeding

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • Patients aged ≥19 with symptomatic aortic stenosis who underwent successful transcatheter aortic valve replacement (TAVR)* (either native valve or valve in valve with any approved/marketed device)
  • A successful TAVI is defined as device success according to the VARC-2(Valve Academic Research Consortium 2) and VARC-3 criteria:
  • correct positioning of a single prosthetic heart valve into the proper anatomical location AND
  • intended performance of the prosthetic heart valve (mean aortic valve gradient <20 mmHg, peak velocity <3 m/s, no moderate or severe prosthetic valve regurgitation) AND
  • absence of periprocedural complications (any type of stroke, life-threatening bleeding, acute coronary artery obstruction requiring intervention, major vascular complication requiring intervention, unresolved acute valve thrombosis, or any requirement of a repeat procedure)
  • Heart Failure with Mildly Reduced or Preserved Ejection Fraction
  • Left ventricular ejection fraction (LVEF) ≥40%
  • structural heart disease_Left ventricular hypertrophy (LVH) or Left atrial enlargement; Left ventricular hypertrophy (LVH) with septal thickness or posterior wall thickness ≥ 1.1 cm or; Left atrial (LA) enlargement with at least one of the following: LA width (diameter) ≥3.8 cm or LA length ≥ 5.0 cm, or LA area ≥ 20cm2, or LA volume ≥ 55mL or LA volume index ≥ 29mL/m
  • NT-proBNP ≥ 300 pg/mL (for patients without ongoing atrial fibrillation) or NT-proBNP must be ≥ 600 pg/mL (for patients with ongoing atrial fibrillation)
  • Patients who voluntarily participated in the written agreement

Who cannot take part

  • Currently receiving therapy with an SGLT2 inhibitor within 4 weeks prior to randomization; discontinuation of current use of SGLT2 inhibitor for the purposes of study enrolment is not permitted
  • Known allergy, hypersensitivity, or previous intolerance to an SGLT2 inhibitors
  • Stroke or transient ischemic attack within 12 weeks prior to enrollment
  • SBP ≥180 mmHg irrespective of treatment or SBP ≥160 mmHg with at least ≥3 antihypertensive drugs at screening or randomization
  • Current ongoing alcoholic or drug addict
  • Participation in other clinical trials, However, where at least one or more conditions are satisfied, it could be an exception according to an investigator's discretion; Participating in the observational study expected no effect on the safety and/or effectiveness evaluation of this trial; Screening failed before any interventional factor is involved; Participants who have completed their involvement in clinical trials and have surpassed a 4-week period since their last administration of the investigational drug; Participated in academic trials like strategic or medical device comparison studies conducted under standard therapy provided that there is no additional risk or a specific procedure to a subject and no interference between this trial and other studies
  • Acute decompensated Heart Failure (exacerbation of chronic Heart Failure) requiring intravenous diuretics, vasodilators, inotropic agents, or mechanical support, or hemodynamic instability following the transcatheter aortic valve replacement procedure
  • Type 1 diabetes mellitus or diabetes ketoacidosis
  • Chronic cystitis and/or recurrent urinary tract infection (≥2 times within 1 year)
  • Heart failure due to any of the following causes; known infiltrative cardiomyopathy (e.g. amyloid, sarcoid, lymphoma, endomyocardial fibrosis, haemochromatosis, Fabry disease), active myocarditis, constrictive pericarditis, cardiac tamponade, known hypertrophic obstructive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVD), or uncorrected primary valvular disease
  • Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalization for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension
  • Current or suspicious malignancy or history of malignancy within 5 years
  • Uncontrolled hypothyroidism or arrhythmia or tachycardia
  • Subjects with non-cardiac co-morbidities with life expectancy less than 12 months
  • HF with reduced ejection fraction (LVEF <40%)
  • Severe renal insufficiency (eGFR <30 ml/min/1.73 m2 of body-surface area based on the Modification of Diet in Renal Disease (MDRD) formula) or end-stage renal disease or requiring dialysis at the time of screening
  • Acute or chronic liver disease with severe impairment of liver function (e.g., ascites, esophageal varices, coagulopathy) or serum levels of transminases or alkaline phosphatase more than two times the upper limit of normal at screening
  • Uncontrolled anaemia or haemoglobin <9g/dl
  • Women of childbearing age who have not reached a consensus on the use of highly effective contraception. Pregnancy or breastfeeding
  • Symptomatic persistent hypotension and/or a systolic blood pressure (SBP) < 95 mm Hg at screening or at randomization
  • Planned major high-risk operation after transcatheter aortic valve replacement (TAVR)

Where in South Korea

  • Bucheon Sejong HospitalBucheon-si, South KoreaContact: Young-jin Choi, MDTaking people
  • Gyeongsang National University Changwon hospitalChangwon, South KoreaContact: Jae-seok Bae, MDTaking people
  • Daegu Catholic University Medical CenterDaegu, South KoreaContact: Jin-bae Lee, MDTaking people
  • Keimyung University - Dongsan Medical CenterDaegu, South KoreaContact: Chul-hyun Lee, MDTaking people
  • Kyungpook National University HospitalDaegu, South KoreaContact: Dong-heon Yang, MDTaking people
  • Yeungnam University Medical CenterDaegu, South KoreaContact: Jeong-youn Bae, Project managerNo longer taking part
  • Chungnam National University HospitalDaejeon, South KoreaContact: Jin-Ok Jeong, MDTaking people
  • The Catholic University of Korea, Daejeon ST.Mary's HospitalDaejeon, South KoreaContact: Man-won Park, MDTaking people
  • Gangneung Asan HospitalGangneung, South KoreaContact: Han-bit Park, MDTaking people
  • Chonnam National University HospitalGwangju, South KoreaContact: Ju-han Kim, MDTaking people
  • Inje University Ilsan Paik HospitalIlsan, South KoreaContact: Seong-wook Kwon, MDTaking people
  • Gachon University Gil HospitalIncheon, South KoreaContact: Woong-cheol Kang, MDTaking people
  • Incheon Sejong HospitalIncheon, South KoreaContact: Rak-kyoung Choi, MDTaking people
  • Inha University HospitalIncheon, South KoreaContact: Sang-don Park, MDTaking people
  • The Catholic University of Korea, Incheon St. Mary's HospitalIncheon, South KoreaContact: Ik-joon Choi, MDTaking people
  • Dong-A Medical CenterPusan, South KoreaContact: Yong-rak Cho, MDTaking people
  • Inje University Pusan Paik HospitalPusan, South KoreaContact: Tae-hyun Yang, MDTaking people
  • Pusan National University HospitalPusan, South KoreaContact: Jung-Hyun Choi, MDTaking people
  • Seoul university Bundang hospitalSeongnam-si, South KoreaContact: In-ho Chae, MDTaking people
  • Asan Medical CenterSeoul, South KoreaContact: Duk-woo Park, MDTaking people
  • Ewha Womans University Mokdong HospitalSeoul, South KoreaContact: In-sook Kang, MDTaking people
  • Ewha Womans University Seoul HospitalSeoul, South KoreaContact: Sang-hoon Shin, MDTaking people
  • Hanyang University Seoul HospitalSeoul, South KoreaContact: Hyungdon Kook, MDTaking people
  • Konkuk University Medical CenterSeoul, South KoreaContact: Bum-seong Kim, MDTaking people
  • Korea University Anam HospitalSeoul, South KoreaContact: Chul-woong Yoo, MDTaking people
  • Korea University Guro HospitalSeoul, South KoreaContact: Cheol-ung Choi, MDTaking people
  • SNU Boramae Medical CenterSeoul, South KoreaContact: Woo-young Jeong, MDTaking people
  • The Catholic Univ. of Korea Eunpyeong St. Mary's hospitalSeoul, South KoreaContact: Jeong-hoon Lee, MDTaking people
  • The Catholic University of Korea St. Vincent's HospitalSuwon, South KoreaContact: Jeong-youn Bae, Project managerNo longer taking part
  • Uijeongbu Eulji Medical Center, Eulji UniversityUijeongbu-si, South KoreaContact: Jeong-youn Bae, Project managerNo longer taking part
  • Ulsan University HospitalUlsan, South KoreaContact: Kyoung-min Park, MDTaking people

About the trial

What the trial wants to find out

The goal of this trial is to to determine whether use of a novel SGLT2 inhibitor, Enavogliflozin 0.3 mg once daily is superior to placebo, when added to standard-of-care, in reducing the composite of major cardiovascular events and Heart Failure events (hospitalization for Heart Failure or urgent Heart Failure visit) among patients who underwent transcatheter aortic valve replacement for severe aortic stenosis and with heart failure with preserved ejection fraction.

The 2 groups in the trial

  • Enavogliflozin GroupTreatment being tested

    0.3 mg 1 tablet once daily

    Treatment: Enavogliflozin

  • placebo as add-on to standard of care treatment groupPlacebo, for comparison

    Placebo matching enavogliflozin

    Treatment: Standard-of-Care

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-Blind, Placebo-controlled Trial to Evaluate Efficacy and Safety of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, Enavogliflozin Compared to Placebo on Reducing Major Cardiovascular Events or Worsening Heart Failure in Patients With Severe Aortic Stenosis Who Underwent Transcatheter Aortic Valve Replacement (TAVR) and With Heart Failure With Preserved Ejection Fraction (HFpEF)
Plain-language title
Tests enavogliflozin for heart failure after aortic valve replacementGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
29 June 2026